Status:
COMPLETED
Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use
Lead Sponsor:
Centre Hospitalier le Mans
Conditions:
Relapsed Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
This retrospective multicenter observational study will provide real-life efficacy and tolerance data for patients with relapsed multiple myeloma (RMM) treated with carfilzomib in the context of nomin...
Eligibility Criteria
Inclusion
- Male or female patients over the age of 18 years
- Patients beginning carfilzomib treatment in the framework of expanded access or compassionate use in France (KRd or Kd regimen)
- Patients who received carfilzomib in first or second MM relapse
- Patients receiving at least one complete course of carfilzomib
Exclusion
- Patients already included in an interventional research protocol using carfilzomib at the time of treatment initiation
- Patients refusing to allow the computerization of their data
- Patients for whom hospital medical records are not accessible
Key Trial Info
Start Date :
August 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT04811508
Start Date
August 4 2020
End Date
December 31 2021
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Du Mans
Le Mans, France, 72000